To shed its mass market tag, Dabur to focus on health juices rather than fruit drinks. While the pharma sector in India may be looking up, for the Dabur Group, the move is in line with its desire to maintain a strong foothold in the FMCG sector that is poised to grow by 16 per cent this financial year compared to the 12 per cent growth rate in pharma.
India's Supreme Court in April rejected a patent for Novartis AG's cancer drug Glivec, saying it was an amended version of a known molecule called imatinib, setting the precedent for more such cases in the country.
Import alert on Ranbaxy's Mohali unit; Strides' injectible arm gets warning letter
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances